Yunnan Baiyao Group has filed a patent for an antibacterial and antiviral pharmaceutical composition. The composition includes various raw materials and can be prepared into medicinal volatile oil. It is claimed that the composition can be used to resist bacteria and viruses, reduce fever, and treat respiratory diseases, including SARS-CoV-2. GlobalData’s report on Yunnan Baiyao Group gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Yunnan Baiyao Group, nanoemulsion cosmetics was a key innovation area identified from patents. Yunnan Baiyao Group's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Antibacterial and antiviral pharmaceutical composition using specific ingredients
A recently filed patent (Publication Number: US20230126992A1) describes an antibacterial and antiviral pharmaceutical composition. The composition includes a volatile oil or aromatic water derived from specific raw materials in specific proportions. The raw materials include Herba pogostemonis, Rhizoma atractylodis, Herba moslae, Folium artemisiae argyi, Flos caryophylli, and Herba menthae haplocalycis. The composition may also contain natural borneol and a pharmaceutical excipient.
The patent claims that the pharmaceutical composition can be prepared in various dosage forms such as spray, distillate medicinal water, aerosol, dropping pill, soft capsule, nasal drop, or preparation for atomization inhalation. The method for preparing the composition involves extracting the volatile oil from the raw materials through steam distillation or supercritical carbon dioxide extraction. Natural borneol is added to the volatile oil to create the pharmaceutical volatile oil. The aromatic water is prepared by soaking the raw materials in water and then distilling them.
The patent also claims that the pharmaceutical composition can be used for its antibacterial and antiviral properties, as well as for clearing heat, reducing fever, and treating respiratory diseases. The method of administration involves administering a therapeutically effective amount of the composition. The patent specifically mentions the potential use of the composition for treating respiratory diseases such as rhinitis and chronic obstructive pulmonary diseases. It also highlights the potential use of the composition for treating the SARS-CoV-2 virus, which causes COVID-19.
In summary, the patent describes an antibacterial and antiviral pharmaceutical composition derived from specific raw materials. The composition can be prepared in various dosage forms and may contain natural borneol and a pharmaceutical excipient. The composition is claimed to have potential therapeutic applications for treating respiratory diseases and combating viral infections, including SARS-CoV-2.
To know more about GlobalData’s detailed insights on Yunnan Baiyao Group, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
